Logo
x

Search

Subscribe Now

Arcutis

PharmaShots Weekly Snapshots (February 26 – March 01, 2024)

PharmaShots Weekly Snapshots (February 26 – March 01, 2024)

  • March 1, 2024
Arcutis Receives the US FDA Approval for Zoryve (roflumilast) to Treat Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Arcutis Receives the US FDA Approval for Zoryve (roflumilast) to Treat Seborrheic Dermatitis in Individuals Aged 9 Years and Older

  • December 18, 2023
Arcutis Reports Interim Results from the P-III (INTEGUMENT-OLE) Trial of Roflumilast for Mild to Moderate Atopic Dermatitis

Arcutis Reports Interim Results from the P-III (INTEGUMENT-OLE) Trial of Roflumilast for Mild to Moderate Atopic Dermatitis

  • September 9, 2023
Arcutis Entered into a Collaboration and License Agreement with Huadong for Roflumilast in Greater China and Southeast Asia

Arcutis Entered into a Collaboration and License Agreement with Huadong for Roflumilast in Greater China and Southeast Asia

  • August 11, 2023
Arcutis Reports the US FDA Acceptance of NDA for Roflumilast to Treat Seborrheic Dermatitis in Individuals Aged ≥9 Years

Arcutis Reports the US FDA Acceptance of NDA for Roflumilast to Treat Seborrheic Dermatitis in Individuals Aged ≥9 Years

  • April 19, 2023
Arcutis Reports the NDA Submission of Roflumilast to the US FDA for the Treatment of Seborrheic Dermatitis

Arcutis Reports the NDA Submission of Roflumilast to the US FDA for the Treatment of Seborrheic Dermatitis

  • February 22, 2023
PharmaShots Weekly Snapshots (January 15 – January 19, 2024)

    PharmaShots Weekly Snapshots (January 15 – January 19, 2024)

    • January 19, 2024
    Insights+: The US FDA New Drug Approvals in December 2023 

      Insights+: The US FDA New Drug Approvals in December 2023 

      • January 17, 2024
      Arcutis Biotherapeutics Highlights Results from the STRATUM Study of Zoryve (Roflumilast) Topical Foam, 0.3% for Seborrheic Dermatitis

        Arcutis Biotherapeutics Highlights Results from the STRATUM Study of Zoryve (Roflumilast) Topical Foam, 0.3% for Seborrheic Dermat...

        • January 15, 2024
        Arcutis Biotherapeutics Reports Results for Zoryve Cream in P-II Trials for the Treatment of Atopic Dermatitis

          Arcutis Biotherapeutics Reports Results for Zoryve Cream in P-II Trials for the Treatment of Atopic Dermatitis

          • January 15, 2024
          PharmaShots Weekly Snapshots (December 18 – December 22, 2023)

            PharmaShots Weekly Snapshots (December 18 – December 22, 2023)

            • December 22, 2023
            Arcutis Receives the US FDA Approval for Zoryve (roflumilast) to Treat Seborrheic Dermatitis in Individuals Aged 9 Years and Older

              Arcutis Receives the US FDA Approval for Zoryve (roflumilast) to Treat Seborrheic Dermatitis in Individuals Aged 9 Years and Older

              • December 18, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.